Vanda Pharmaceuticals Inc. is a biopharmaceutical company based in Washington, D.C., focused on delivering innovative solutions for unmet medical needs in central nervous system disorders and sleep medicine. The company boasts a robust pipeline, emphasizing its commitment to developing and commercializing therapies that enhance patient outcomes. With its strategic focus on niche markets and significant investments in research and development, Vanda is well-positioned to drive sustainable growth and make impactful contributions to the healthcare industry. Show more

Location: 2200 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, UNITED STATES, 20037, Washington, DC, 20037, USA | Website: https://www.vandapharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

445.6M

52 Wk Range

$3.81 - $9.60

Previous Close

$7.54

Open

$7.58

Volume

956,540

Day Range

$7.55 - $7.96

Enterprise Value

162.8M

Cash

70.02M

Avg Qtr Burn

-31.63M

Insider Ownership

7.21%

Institutional Own.

75.01%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PONVORY® (ponesimod) Details Multiple sclerosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NEREUS (tradipitant) Details Motion sickness	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fanapt® (iloperidone) Details Mental health, Bipolar depression, Bipolar disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fanapt® (iloperidone) Details Schizophrenia and PDP (Parkinson's disease psychosis)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HETLIOZ® (tasimelteon) Details SMS (Smith-Magenis Syndrome)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HETLIOZ® (tasimelteon) Details Non-24-Hour Sleep-Wake Disorder (Non-24)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bysanti™ (milsaperidone) Details Bipolar I manic and mixed episodes and schizophrenia	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imsidolimab (IL-36 Inhibitor) Details Generalized Pustular Psoriasis	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imsidolimab (IL-36 Inhibitor) Details Generalized Pustular Psoriasis	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HETLIOZ® (tasimelteon) Details Insomnia	sNDA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HETLIOZ® (tasimelteon) Details Jet Lag	sNDA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tradipitant Details Gastroparesis	NDA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fanapt/Iloperidone LAI (D2 Antagonist) Details Schizophrenia, Relapse Prevention	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bysanti™ (milsaperidone) Details Mental Health, Major depressive disorder	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tradipitant Details Nausea and Vomiting in Obesity (After GLP-1R Agonist Use)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VQW-765 Details Social Anxiety Disorder	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VSJ-110 Details Dry eye disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trichostatin A (VTR-297) Details Onychomycosis, Fungal infections	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VCA-894A Details Charcot-Marie-Tooth disease, axonal, type 2S , Neuropathy	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tradipitant Details Atopic pruritus , Atopic dermatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trichostatin A (VTR-297) Details Leukemia, Multiple myeloma, Lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tradipitant \| ODYSSEY VLY-686-3501 Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.